Skip to main content
Swing Capital

Aurobindo Pharma Ltd

NSE: AUROPHARMA BSE: 524804Pharma

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.(Source : 202003 Annual Report Page No:159)

₹1,509
52W: ₹1016 — ₹1528
PE 40.9 · Book ₹369 · +309% vs book
Market Cap₹87,652 Cr
Stock P/E40.9Price to Earnings
ROCE10.8%Return on Capital
ROE8.65%Return on Equity
Div. Yield0.26%Face Value ₹1

Strengths

  • +Company's working capital requirements have reduced from 74.4 days to 32.4 days

Weaknesses

  • −Stock is trading at 4.15 times its book value
  • −The company has delivered a poor sales growth of -3.95% over past five years.
  • −Company has a low return on equity of 8.68% over last 3 years.

Shareholding Pattern

Promoters51.82%
FIIs15.24%
DIIs25.82%
Public7.08%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters51.8%51.82%▲0.051.82%51.82%51.82%51.82%51.82%51.82%
FIIs16.73%16.59%▼0.116.29%▼0.315.33%▼1.014.38%▼0.914.21%▼0.213.95%▼0.315.24%▲1.3
DIIs24.77%25.14%▲0.425.21%▲0.126.23%▲1.026.93%▲0.727.6%▲0.727.66%▲0.125.82%▼1.8
Public6.69%6.45%▼0.26.67%▲0.26.61%▼0.16.88%▲0.36.37%▼0.56.55%▲0.27.08%▲0.5

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales2,6692,6922,8942,4602,8252,9172,7322,8482,7902,747
Expenses2,1242,2102,1191,9612,1042,2032,1352,0522,0651,958
Operating Profit545482775499721713597796725789
OPM %20%18%27%20%26%24%22%28%26%29%
Net Profit416624579329538472408559581582
EPS ₹7.110.659.885.629.258.137.039.6310.0110.02

AI Insights

Revenue Trend

TTM revenue at ₹11,117Cr, up 1.7% YoY. OPM at 26%.

Debt Position

Borrowings at ₹4,429Cr. Debt-to-equity ratio: 0.21x. Healthy balance sheet.

Capex Cycle

CWIP at ₹209Cr (9% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 25.82% (+10.09pp change). FIIs: 15.24% (-8.88pp change). Promoters hold 51.82%.

Margin & Efficiency

ROCE declining from 29% (Mar 2014) to 11% (Mar 2025). Working capital days: 32.

Valuation

PE 40.9x with 10.8% ROCE. Price is 309% above book value of ₹369. Dividend yield: 0.26%.

Recent Announcements